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Context and Significance {#sec1}
========================

**Obese children are often stigmatized and experience health problems such as diabetes and heart disease in later life. Finding the cause of their obesity may lead to new treatments. In some cases, faulty genes underly severe childhood obesity. In this study, researchers in the United Kingdom and their colleagues aimed to discover new genes linked to severe childhood obesity and found three candidates. One gene, *PHIP*, affected childhood obesity with learning difficulties. They demonstrate that *PHIP* works by controlling another gene, *POMC*, which is known to regulate appetite. This finding means that children with faults in the gene *PHIP* may benefit from existing treatments. Further studies will be required to fully evaluate these genes in a broader context.**

Introduction {#sec2}
============

The rising prevalence of obesity is largely driven by the consumption of high-calorie foods and reduced levels of physical activity at work and in leisure time, which contribute to sustained positive energy balance and weight gain. However, family, twin, and adoption studies have consistently demonstrated that 40%--70% of the variation in body weight in a given environment is attributable to genetic variation within the population ([@bib3]). As such, finding even a single gene that contributes to the regulation of body weight is important as it provides insights into the mechanisms underlying the development of obesity and may identify potential targets for future weight loss therapy.

To date, several different approaches have been used to identify genes involved in human energy homeostasis. Candidate gene studies led to the identification of very rare variants that cause monogenic forms of severe obesity mostly by impacting the function of proteins involved in the central leptin-melanocortin pathway ([@bib12], [@bib47], [@bib53], [@bib60]). These findings have had diagnostic value for patients and have paved the way for stratified therapy as seen with the treatment of congenital leptin deficiency by recombinant leptin ([@bib14]) and of *POMC* and *LEPR* deficiency by the melanocortin 4 receptor (*MC4R*) agonist setmelanotide ([@bib7], [@bib29]).

By focusing on more common forms of genetic variation (minor allele frequency \[MAF\] \> 5%) in population-derived cohorts, genome-wide association studies (GWAS) have identified over 250 loci that are associated with body mass index (BMI) and/or obesity (defined as a BMI \> 30 kg/m^2^), mostly through modest effects on neuronal genes ([@bib2], [@bib16], [@bib24], [@bib45], [@bib58], [@bib39]). While cumulatively these approaches have provided a framework for understanding the genetic architecture of weight regulation and susceptibility to obesity, a substantial proportion of the heritability of human obesity (including severe childhood-onset obesity) has yet to be explained. There is no biological reason why genetic risk factors for common complex traits/diseases should fall neatly into these two categories, as we ([@bib5]) and others ([@bib27], [@bib42]) have suggested. We therefore hypothesize that variants that contribute to this "missing heritability" in obesity will include a range of allele frequencies and effect sizes in a continuum of causality ([@bib27]), as seen for other complex traits ([@bib42]), and explore this in the work we present here.

Results {#sec3}
=======

Rare Variants Implicate Three New Genes in Human Energy Homeostasis {#sec3.1}
-------------------------------------------------------------------

Here, we studied a cohort of European ancestry individuals with severe childhood-onset obesity (SCOOP) in whom known causes of monogenic obesity, such as congenital leptin deficiency and *MC4R* mutations, had been excluded ([STAR Methods](#sec5){ref-type="sec"}). Children were recruited into the cohort if they had a BMI standard deviation score (BMI SDS) greater than three and age of onset below 10 years ([@bib64]) ([STAR Methods](#sec5){ref-type="sec"}). Our study design, focused on early-onset severe obesity, was aimed at increasing power to identify genes with an excess burden of rare, functionally significant variants with moderate to large effects on the phenotype ([STAR Methods](#sec5){ref-type="sec"}). We analyzed whole-exome sequencing (WES) data from 927 SCOOP cases ([@bib17], [@bib61]) and 4,057 UK healthy blood donors from the INTERVAL cohort (stage 1; [STAR Methods](#sec5){ref-type="sec"}; [Figures 1](#fig1){ref-type="fig"} and [S1](#mmc1){ref-type="supplementary-material"}). To test for different genetic effects, we performed single-variant ([Table S1](#mmc2){ref-type="supplementary-material"}) and three nested gene-based analyses: (1) burden of very rare (MAF \< 0.025%) predicted loss-of-function (LOF) variants (LOF analysis), (2) burden of very rare (MAF \< 0.025%) predicted deleterious variants by five different *in silico* programs (LOF and missense \[STRICT\] analysis), and (3) SKAT-O analysis of variants with MAF \< 1% and predicted deleterious by a single program (LOF and missense \[BROAD\] analysis) ([Figures 1](#fig1){ref-type="fig"}, [S1](#mmc1){ref-type="supplementary-material"}, and [S2](#mmc1){ref-type="supplementary-material"}; [Tables S2](#mmc3){ref-type="supplementary-material"}A--S2C; [STAR Methods](#sec5){ref-type="sec"}).Figure 1Flow Diagram of Approach and Headline ResultsThe overall analysis and main results from this study. Whole-exome sequence data from SCOOP and INTERVAL participants were analyzed as single-variant, gene-base, and gene set analyses. Overall, 48 variants from single-variant and gene-based analysis and 9 genes from gene-based analysis were identified and taken forward to stage 2 validation, by genotyping or targeted-sequenced. Combined stage 1 and stage 2 significant results were found in three genes (*PHIP*, *DGKI*, and *ZMYM4*), which were taken for functional follow-up. In parallel, gene set analysis performed on five primary gene sets (obesity, syndromic obesity, DDG2P, Constrained \[pLI \> 0.9\], Unconstrained \[pLI ≤ 0.9\], and Genes Mapping to known Obesity or BMI GWAS loci) is represented. The strongest enrichment, which was detected in loss-of-function constrained genes (pLI \> 0.9) mapping to obesity or BMI-associated GWAS loci, is shown (Genes in GWAS loci, pLI \> 0.9). Related to [Figure S1](#mmc1){ref-type="supplementary-material"}.

We identified nine genes with an excess burden of variants from LOF, STRICT, and BROAD analyses in cases versus controls, meeting the arbitrary threshold of p \< 10^−4^, which we took forward for stage 2 analysis ([Figure 1](#fig1){ref-type="fig"}; [STAR Methods](#sec5){ref-type="sec"}; [Tables S2](#mmc3){ref-type="supplementary-material"}A--S2C). Targeted sequencing was performed in an additional unrelated 1,810 SCOOP cases and 2,647 controls from the Fenland cohort (stage 2), and validation of reported variants was undertaken by Sanger sequencing ([STAR Methods](#sec5){ref-type="sec"}). Validated variants from stage 1 and stage 2 results were combined in meta-analysis. Directionally consistent association with obesity in stage 2, and stronger p values from stage 1 + 2 in either LOF or STRICT analysis was detected in three genes. For each gene, we highlight the most significant association result: p~meta-LOF~ = 1.23 × 10^−5^ *PHIP* (pleckstrin homology domain interacting protein), p~meta-STRICT~ = 7.93 × 10^−4^ *DGKI* (diacylglycerol \[DAG\] kinase iota), and p~meta-LOF~ = 3.19 × 10^−7^ *ZMYM4* (zinc-finger-MYM-type-containing 4) ([Table 1](#tbl1){ref-type="table"}). *ZMYM4* results are significant after Bonferroni correction for all genes in the genome (p \< 2.5 × 10^−6^). In all, we see strong evidence of winner's curse with much larger odds ratios in stage 1, compared to stage 2 analysis.Table 1Burden of Very Rare Variants (MAF \< 0.025%) Enriched in Obese Cases Compared to ControlsStage 1Stage 2Stage 1 + Stage 2GeneTestp ValueNumber of Variants/Case Alleles/Control AllelesOR (adj OR \[95% CI\])p ValueNumber of Variants/Case Alleles/Control AllelesOR (adj OR \[95% CI\])p ValueOR (adj OR \[95% CI\])*PHIP*STRICT3.67 × 10^−5^13/9/66.57 \[2.34--18.45\]0.20708/5/32.45 \[0.59--10.27\]9.81 × 10^−5^4.35 \[1.88--10.06\]LOF2.84 × 10^−5^4/4/0Inf (39.41 \[2.12--732.02\])0.03613/3/0Inf (10.26 \[0.53--198.57\])1.23 × 10^−5^Inf (39.74 \[2.27--695.83\])*DGKI*STRICT4.95 × 10^−6^9/7/215.32 \[3.18--73.77\]0.58837/4/41.47 \[0.37--5.86\]7.93 × 10^−4^4.81 \[1.78--13.01\]LOF0.03641/1/0Inf (13.13 \[0.53--322.53\])0.22651/1/0Inf (4.44 \[0.18--109.07\])0.0243Inf (12.36 \[0.59--257.51\])*ZMYM4*STRICT0.016012/7/103.06 \[1.17--8.05\]0.19346/4/22.93 \[0.54--16.02\]0.00682.70 \[1.19--6.12\]LOF2.94 × 10^−7^5/6/0Inf (56.93 \[3.21--1010.63\])0.22651/1/0Inf (4.39 \[0.18--107.89\])3.19 × 10^−7^Inf (53.48 \[3.05--936.37\])*ZNF32*STRICT2.84 × 10^−5^4/4/0Inf (39.41 \[2.12--732.02\])--0/0/0--LOF0.03641/1/0Inf (13.13 \[0.53--322.53\])--0/0/0--[^5]

In a fourth gene, *ZNF32* (zinc-finger protein 32), very rare predicted deleterious variants were only observed in stage 1 cases (p~STRICT~ = 2.84 × 10^−5^; [Table 1](#tbl1){ref-type="table"}). *ZNF32* is a zinc-finger protein of uncharacterized function and with a ubiquitous expression pattern ([Figure S3](#mmc1){ref-type="supplementary-material"}A). We attempted to gain independent evidence of its role in obesity by generating an engineered mouse mutant; however, homozygous *ZNF32* ^*em1(IMPC)Wtsi*^ do not display any obvious phenotype (data not shown). We present our results here to invite others to explore this gene in their cohorts, but at this stage we feel the evidence is insufficient to link this gene with obesity.

Though not independent, analysis using stage 1 cases and external controls (to increase sample size) also provides support (*PHIP*, p~LOF~ = 4.9 × 10^−4^; *DGKI*, p~STRICT~ = 0.10; *ZMYM4*, p~LOF~ = 7.10 × 10^−5^; *ZNF32*, p~STRICT~ = 2.14 × 10^−2^; [Table S3](#mmc1){ref-type="supplementary-material"}; [STAR Methods](#sec5){ref-type="sec"}). To further strengthen the evidence for or against the role of these genes in extreme obesity, we examined 431 adults with BMI \> 40 kg/m^2^ from the UK10K project (approximately equivalent to the BMI \> 3 SDs used to define severe obesity in children in SCOOP) and 984 non-overlapping adult controls from the 1958 Birth Cohort ([STAR Methods](#sec5){ref-type="sec"}). We identified between 0 and 2 STRICT or LOF very rare variants in these four genes in adult cases and 0--3 STRICT or LOF very rare variants in adult controls, and while the 95% CIs overlapped estimates from children, they also included the null ([Table S4](#mmc1){ref-type="supplementary-material"}). Single-variant and BROAD stage 1 + 2 combined results did not yield additional significant association results ([Tables 2](#tbl2){ref-type="table"}, [S5](#mmc4){ref-type="supplementary-material"}, and [S6](#mmc6){ref-type="supplementary-material"}A; [STAR Methods](#sec5){ref-type="sec"}).Table 2Burden of Rare Variants (MAF \< 1%) from BROAD Analysis Enriched in Obese Cases Compared to ControlsStage 1Stage 2Stage 1 + Stage 2Genep ValueNumber of Variants/Case Alleles/Control AllelesORp ValueNumber of Variants/Case Alleles/Control AllelesORp ValueOR*PHIP*0.005938/14/292.11 \[1.12--4\]0.008622/18/92.95 \[1.33--6.57\]4.58 × 10^−4^2.4 \[1.5--3.84\]*DGKI*0.013430/18/401.97 \[1.13--3.44\]0.891027/14/201.03 \[0.52--2.03\]0.09981.35 \[0.88--2.07\]*ZMYM4*0.07134/25/701.56 \[0.99--2.47\]0.491125/57/890.94 \[0.68--1.31\]0.44931.38 \[1.06--1.8\]*ZNF32*0.00336/4/28.76 \[1.6--47.81\]1.00003/2/30.98 \[0.16--5.85\]0.08693.53 \[1.08--11.58\][^6]

Finally, through analysis focused on 43 genes previously known to harbor mutations causal of monogenic/syndromic obesity ([Table S8](#mmc6){ref-type="supplementary-material"}A), we find 12 genes have nominal evidence of a burden of BROAD, STRICT, or LOF very rare variants in our obese cases compared to controls (stage 1 samples, p \< 0.05; [Table S2](#mmc3){ref-type="supplementary-material"}D).

*PHIP* Variants Are Associated with Obesity with and without Development Delay {#sec3.2}
------------------------------------------------------------------------------

*PHIP* is of particular interest, as deletions and frameshift mutations in this gene have been reported in patients with developmental delay, intellectual disability, and dysmorphic features, and in some cases, patients were reported to be overweight ([@bib9], [@bib22], [@bib63]). In keeping with previous reports, some probands in SCOOP had learning difficulties and dysmorphic features ([Table 3](#tbl3){ref-type="table"}). Repeat analysis of our obesity cases stratified by the presence/absence of developmental delay demonstrated a very strong association of a burden of *PHIP* very rare LOF variants with obesity in the presence of developmental delay (OR~LOF_stage1+2~ = 95.01, CI~95~ = 5.11,1765.21, p~LOF_stage1+2~ = 3.19 × 10^−10^; [Figure 2](#fig2){ref-type="fig"}). We also found moderate evidence for association with obesity in the absence of developmental delay (OR~LOF_stage1+2~ = 26.95, CI~95~ = 1.39,521.79, p~LOF_stage1+2~ = 0.0006; [Figure 2](#fig2){ref-type="fig"}; [Table S7](#mmc1){ref-type="supplementary-material"}). Where samples from one or both parents were available, we found that 3 probands had inherited the variant from an overweight/obese parent (A389T, R409C, and T1506A), 3 variants (R250X, F1414S, and c.3536-4_3540delTTAGATATT) were found *de novo*, and one variant (found in two unrelated probands) was inherited from a normal weight parent (T1506A) ([Table 3](#tbl3){ref-type="table"}). The absence of severe obesity in some family members carrying *PHIP* STRICT missense and LOF variants, the absence of developmental delay in some probands with LOF mutations ([Table 3](#tbl3){ref-type="table"}), and the presence of STRICT missense variants in control participants without obesity (6/9 controls who were carriers of very rare STRICT variants had a BMI \< 30 kg/m^2^) suggest variable penetrance.Table 3Phenotypes Seen in Carriers of Rare Variants in *PHIP*, *DGKI*, and *ZMYM4*VariantAge (Years)SexBMI (SDS)Height (SDS)Bwt SDSLearning DifficultiesDysmorphic FeaturesAutistic FeaturesHyperactivityAggressionAnxiety or DepressionInsulin (pmol/L)Glucose (mmol/L)**PHIP**R250X[a](#tblfn1){ref-type="table-fn"}6F25 (3.6)111 (−0.9)0.6T289P7.7F34 (4.2)133 (1.3)1.5✓✓1343.8A389T5.1F40 (6.0)114 (1.1)2.21464.7A389T[b](#tblfn2){ref-type="table-fn"}46M541731715.3R409C1.4F24 (3.7)84 (1.6)−2.9✓✓✓✓475.1R409C[b](#tblfn2){ref-type="table-fn"}34M38175R721X44.3F74150\@9.1Q1343X17.2F43 (3.8)151 (−2.1)−0.1✓✓208[c](#tblfn3){ref-type="table-fn"}5.9F1414S[a](#tblfn1){ref-type="table-fn"}20.7M40188−0.9✓✓✓✓✓398[c](#tblfn3){ref-type="table-fn"}6K1443TfsX117.6F35 (4.3)119 (−1.1)1.7✓✓424.4T1506A2.4F23 (3.8)102 (3.8)1.6✓2925.8T1506A[b](#tblfn2){ref-type="table-fn"}44M21T1506A15M46 (4.0)168 (−0.1)0✓985.1T1506A[b](#tblfn2){ref-type="table-fn"}54M29R1718S22.7M40170−1.81005.4c.823-2A\>G7.9M27 (3.5)135 (1.4)0.3✓✓✓575.5c.1524+1G\>T15.5M35 (3.2)176 (0.6)0.23✓✓1545.2c.3536-4_3540 delTTA\
GATATT[a](#tblfn1){ref-type="table-fn"}13.1F49 (4.2)161 (0.7)−0.9✓1445.3**DGKI**D833N15.3F45 (4.0)166 (0.5)−0.21444.6L430R9.1F26 (2.9)132 (−0.2)1.3Q265X3.6M22 (3.6)113 (3.3)−0.8✓σ324.7L192F12.6M31 (3.1)151 (−0.1)−0.1413.1**ZMYM4**N89S15.5F39 (3.5)161 (−0.4)0.1✓1364.6K163Rfsx1011.1M28.3 (3.0)152 (1.2)0.1244.2R379C1.2F26 (4.5)84 (3.0)0.536K387N7.8M25 (3.3)131 (0.8)0.6✓303.9[^7][^8][^9][^10]Figure 2Detailed *PHIP* Association ResultsResults for BROAD, STRICT, and LOF analyses for *PHIP* variants are shown overall (gray), in obese patients with developmental delay (red), and in obese patients without developmental delay (blue). ORs are represented by diamonds with 95% CI shown by dashed lines. Across all analyses, there is a trend for greater ORs for increasing stringency of the test (BROAD \< STRICT \< LOF). Related to [Table S7](#mmc1){ref-type="supplementary-material"}.

*PHIP* Regulates *POMC* Transcription in Cells {#sec3.3}
----------------------------------------------

We performed experiments in cells to explore the potential mechanisms by which *PHIP* might regulate body weight and to test the functional consequences of the 17 very rare coding variants found in cases and controls ([Figure 3](#fig3){ref-type="fig"}A). Human PHIP exists as two isoforms with distinct cellular localizations ([Figure 3](#fig3){ref-type="fig"}B). A short cytoplasmic PHIP (104 kDa) isoform interacts with insulin receptor substrate (IRS)-1 and -2 and is required for insulin and insulin-like growth factor (IGF-1) signaling ([@bib13]). A long (230-kDa) PHIP isoform is exclusively localized in the nucleus. Nuclear PHIP (synonyms DDB1- and CUL4-associated factor 14 \[DCAF14\] or replication initiation determinant protein \[REPID\]) is known to bind directly to chromatin to promote initiation of DNA replication and gene transcription ([@bib21]). It also mediates effects on post-natal growth ([@bib36]), β cell growth, regulation, and survival ([@bib49]). Three variants affected splice donor/acceptor sites and were predicted *in silico* to lead to exon skipping/intron retention and result in LOF of the long isoform of *PHIP* ([Figure 3](#fig3){ref-type="fig"}A).Figure 3Functional Characterization of Obesity-Associated Variants in *PHIP*(A) Mapping of human *PHIP* coding and splice-site variants identified in cases only (red), controls only (blue), and in cases and controls (green) on the full-length *PHIP* isoform. One variant was found in two unrelated probands (underlined); some variants were found in probands who also had developmental delay (^∗^).(B) Representative confocal fluorescence microscopy images showing PHIP localization in the nucleus and the cytoplasm of COS7 cells. Blue, nuclei; green, antibody against endogenous PHIP. Scale bar, 100 μm.(C) Overexpression of WT PHIP potentiates POMC transcription in basal and leptin-stimulated conditions. n = 15, mean + SEM, two-tailed unpaired t test with Welch's correction, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(D) Effect of human PHIP mutants on POMC transcription compared to WT in basal conditions. n = 4--6, mean + SEM, ordinary one-way ANOVA with multiple comparisons to WT, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(E) Dominant-negative effect of human PHIP mutants in POMC transcription in basal conditions. n = 3, mean + SEM, ordinary one-way ANOVA with multiple comparisons to 0 ng, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(F) Representative confocal fluorescence microscopy images showing cytoplasmic protein localization of PHIP mutants in basal conditions.(G) Nuclei to cytoplasm ratio of PHIP subcellular localization. n = 3, mean + SEM, two-tailed unpaired t test with Welch's correction, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(H) Nuclear to cytoplasmic ratio in variants found only in cases in comparison to controls. Lines represent medians and crosses represent means. Dashed lines span from the minimum to maximum values. Wilcoxon rank-sum test, ^∗∗^p = 0.004. Related to [Figures S4](#mmc1){ref-type="supplementary-material"} and [S5](#mmc1){ref-type="supplementary-material"}.

Here, using immunoprecipitation, we showed that cytoplasmic PHIP interacts with IRS-2 in cells stimulated with leptin ([Figure S4](#mmc1){ref-type="supplementary-material"}A); however, this interaction is not required for and does not modulate leptin-mediated phosphorylation of STAT3 or ERK1/2, key signaling pathways involved in energy homeostasis ([Figure S4](#mmc1){ref-type="supplementary-material"}B). We next investigated whether nuclear PHIP could directly affect the transcription of pro-opiomelanocortin (POMC), a neuropeptide that mediates the appetite-suppressing effects of leptin. Using a POMC luciferase reporter assay, we found that wild-type (WT) PHIP potentiated POMC transcription in the absence of leptin ([Figure 3](#fig3){ref-type="fig"}C); all PHIP mutants decreased POMC transcription ([Figure 3](#fig3){ref-type="fig"}D). Seven mutants repressed POMC transcription below levels seen for the null mutation R250X. In co-transfection experiments with varying concentrations of WT and mutant PHIP, four of these mutants (T289P, D594E, Q1343X, and R1505Q) exert a dominant-negative effect, repressing POMC transcription by WT PHIP in a dose-dependent manner ([Figure 3](#fig3){ref-type="fig"}E). Using fluorescent microscopy, we found that most mutants did not alter cellular localization of PHIP, although variants found in cases led to a significant decrease in the ratio of nuclear:cytoplasmic PHIP compared to controls (p = 0.004) ([Figures 3](#fig3){ref-type="fig"}F--3H, [S4](#mmc1){ref-type="supplementary-material"}, and [S5](#mmc1){ref-type="supplementary-material"}). This finding suggests that a reduction in the amount of nuclear PHIP available to enhance POMC transcription (with or without leptin) may contribute to the development of obesity. Leptin stimulation rescued the effects of some, but not all, PHIP mutants on POMC transcription ([Figure S4](#mmc1){ref-type="supplementary-material"}).

*PHIP* Variant Carriers Exhibit Maladaptive Behaviors {#sec3.4}
-----------------------------------------------------

*Phip* null mice exhibit a 40% growth deficit by weaning, develop hypoglycemia, and do not survive beyond 4--5 weeks ([@bib36]). In keeping with the growth phenotype seen in null mice, 5 of 13 *PHIP* variant carriers on whom data was available ([Table 3](#tbl3){ref-type="table"}) were born with low birthweight for gestational age. In some cases, there was evidence of rapid catch-up growth in early childhood (R409C), whereas other probands remained short (Q1343X) ([Table 3](#tbl3){ref-type="table"}). In addition, some variant carriers reported hyperphagia and developed insulin resistance and early type 2 diabetes ([Table 3](#tbl3){ref-type="table"}). Maladaptive behaviors, reminiscent of those seen in carriers of variants in *SH2B1 (*[@bib12]), another PH domain-containing protein involved in leptin and brain-derived neurotrophic factor (BDNF)-mediated signaling, were reported in several probands in this study and in previous clinical case series. Taken together, the combined genetic and functional data provide compelling evidence that *PHIP* is involved in human obesity with and without developmental delay. *PHIP* variants are likely to impact the transcription of multiple downstream target genes, which may in part explain the variability in clinical phenotype observed, which is not simply explained by the results of functional assays used.

*DGKI* Is Associated with Obesity in Humans and Fat Mass in Mice {#sec3.5}
----------------------------------------------------------------

Next, we studied *DGKI*, which is expressed in numerous brain regions (hippocampus, hypothalamus, caudate nucleus, and cortex) and in the thyroid ([STAR Methods](#sec5){ref-type="sec"}; [Figure S3](#mmc1){ref-type="supplementary-material"}B), making it a plausible DGK isoform to be involved in energy homeostasis and metabolism. DAG kinases terminate DAG signaling and are important regulators of long-term potentiation and long-term depression, cellular mechanisms involved in synaptic plasticity ([@bib33]). Common variants in the *DGKI* gene region have been associated with dyslexia ([@bib43]); the patient with the nonsense mutation (Q265X) was reported to have speech and language delay ([Table 3](#tbl3){ref-type="table"}). Delayed habituation to novel environments has previously been reported in *Dgki* knockout mice ([@bib66]).

Here, we engineered mutant *Dgki*^*em1(IMPC)Wtsi*^ mice, and utilizing the Sanger Institute mouse phenotyping pipeline we provide preliminary evidence supporting a role of *Dgki* in energy homeostasis in mice ([STAR Methods](#sec5){ref-type="sec"}). Phenotyping of homozygous *Dgki*^*em1(IMPC)Wtsi*^ mice suggests these mice have increased fat mass and fat percentage, lower bone mineral density, and higher plasma glycerol (males) ([STAR Methods](#sec5){ref-type="sec"}; [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}). However, metabolic phenotyping after exposure to a high-fat diet will be required to further investigate the impact of this gene deletion in energy homeostasis and to gain mechanistic insights.

*ZMYM4* Is a Novel Gene Linked to Human Obesity {#sec3.6}
-----------------------------------------------

*ZMYM4* encodes a poorly characterized protein with a predicted central zinc-finger domain, a proline-rich region, and a C-terminal DUF3504 domain, the latter suggesting it may function as a transcriptional activator or repressor ([@bib28]). It has a broad tissue expression pattern ([STAR Methods](#sec5){ref-type="sec"}; [Figure S3](#mmc1){ref-type="supplementary-material"}C), is predicted to be an LOF intolerant gene (pLi = 1.00) ([@bib34]), and has not been previously linked to obesity or metabolism. LOF intolerant genes are those in which strong negative selection has meant that the gene has fewer LOF mutations in the general population than expected, presumably because of their impact on reproductive fitness. Other than mild learning difficulties, there were no distinctive phenotypes other than severe obesity in variant carriers ([Table 3](#tbl3){ref-type="table"}).

To gain further insight into *ZMYM4* function, we generated mice homozygous for the *Zmym4*^*em1(IMPC)Wtsi*^ allele. In keeping with *ZMYM4* being an LOF intolerant gene, we found that homozygous *Zmym4*^*em1(IMPC)Wtsi*^ mice are pre-weaning lethal. No homozygous mice were detected from 56 offspring, while 14 from 56 offspring would be expected (Fisher's exact test, p \< 0.0001; [STAR Methods](#sec5){ref-type="sec"}). More sophisticated models targeting allele loss in specific tissues or detailed phenotyping in heterozygous *Zmym4*^*em1(IMPC)Wtsi*^ mice will be required to further elucidate the physiological role of this gene.

Genes in BMI GWAS Loci Are Enriched for Very Rare Predicted Deleterious Variants in Severe Obesity {#sec3.7}
--------------------------------------------------------------------------------------------------

Lastly, we investigated whether particular groups of genes, as a gene set, were enriched in very rare predicted deleterious variants in severe early-onset obesity cases compared to controls. These analyses can overcome some of the power limitations when testing genes individually: though individual genes may have insufficient evidence of association with severe early-onset obesity, collectively, gene sets may be shown to associate with obesity. We performed analyses on 10 primary gene sets ([Table S8](#mmc6){ref-type="supplementary-material"}; [STAR Methods](#sec5){ref-type="sec"}).

In gene set analyses, we found that the set of 157 genes mapping to BMI and obesity GWAS loci (GWAS set) was enriched for very rare functional variants in childhood obesity cases (OR~*STRICT*~ = 1.18, CI~95~ = 1.03,1.18, p~*perm-STRICT*~ = 1.63 × 10^−2^; OR~LOF~ = 1.39, CI~95~ = 1.07,1.80, p~*perm-LOF*~ = 1.39 × 10^−2^; [Figure 4](#fig4){ref-type="fig"}A; [Table S9](#mmc7){ref-type="supplementary-material"}A). This provides a compelling rationale for sequencing this group of genes in additional cases and controls, to identify novel variants that may have stronger effects on severe early-onset obesity, and which may yield potential novel drug targets.Figure 4Gene Set Analysis(A) Gene set enrichment analysis for a burden of BROAD, STRICT, and LOF variants in cases compared to controls across 10 primary gene sets. Obesity 1A (monogenic obesity genes, 11 genes), Obesity 1B (9 genes, monogenic obesity genes where *LEP* and *MC4R* were removed), Syndromic 2 (syndromic obesity genes, 32 genes), DDG2P 3A (developmental disorder dominant genes causal through missense or LOF mutations, 360 genes), DDG2P 3B (developmental disorder dominant genes causal through LOF mutations 274 genes), DDG2P 3C (developmental disorders with brain abnormalities dominant genes causal through missense or LOF mutations, 187 genes), DDG2P 3D (developmental disorders with brain abnormalities dominant genes causal through LOF mutations 147 genes), pLI \> 0.9 4A (LOF intolerant genes, 3,488 genes), pLI ≤ 0.9 4B (LOF tolerant genes, 14,753 genes), GWAS 5 (genes mapping to BMI/obesity GWAS loci based on GWAS catalog data, 157 genes). Results for a combined subcategory of pLI \> 0.9 and GWAS (4A and 5, 53 genes) are also shown. Gene sets are described in [Table S8](#mmc6){ref-type="supplementary-material"} and detailed gene set results are in [Table S9](#mmc7){ref-type="supplementary-material"}. Odds ratios (ORs, y axis) and 95% CI (dashed lines) are shown for each gene set and analysis.(B) Odds ratios (ORs) for obesity cases with developmental delay (DD, x axis) and ORs for obesity cases without developmental delay (not DD, y axis) are shown for each of the gene sets shown in (A). p value strength is indicated by size of the circle, for obesity DD (pink) and obesity not DD (blue) in semi-transparent circles. LOF intolerant genes overall (4A) and all of DDG2P (3A--3D) have larger ORs and are more significantly associated with obesity DD. In contrast, GWAS genes that are also LOF intolerant (4A&5) show equivalent ORs and statistical association with obesity DD and obesity not DD. Related to [Tables S8](#mmc6){ref-type="supplementary-material"} and [S9](#mmc7){ref-type="supplementary-material"}.

We also noted that genes that are normally depleted in LOF mutations in the population, known as LOF intolerant genes (pLI \> 0.9) ([@bib34]), were more common in this GWAS set compared to all genes in the genome (33.8% versus 19.1%, p~ChiSq-Ind~ = 3.11 × 10^−6^). In secondary analyses, we found that this subset of 53 LOF intolerant genes among the 157 genes in the GWAS set was further enriched in very rare deleterious variants in our obese cases compared to controls (OR~*STRICT*~ = 1.34, CI~95~ = 1.14,1.58 p~*perm-STRICT*~ = 8.00 × 10^−4^; OR~LOF~ = 3.54, CI~95~ = 1.80,6.95, p~*perm-LOF*~ = 5.00 × 10^−4^) ([Figure 4](#fig4){ref-type="fig"}A; [Table S9](#mmc7){ref-type="supplementary-material"}D). The OR for putative LOF variants in this gene set of 53 genes was similar to the estimate for the gene set of monogenic obesity genes ([Figure 4](#fig4){ref-type="fig"}A). This suggests that some of these genes may harbor rare variants of potentially larger effect size affecting severe childhood obesity.

LOF Intolerant Genes Are Enriched in Very Rare Deleterious Variants in Obese Cases with Developmental Delay {#sec3.8}
-----------------------------------------------------------------------------------------------------------

As severe obesity is not normally reproductive lethal, it was surprising to find that 53 LOF intolerant genes among the GWAS set were particularly enriched for very rare deleterious variants in our cases. To further explore these results, we stratified our cases into those with developmental delay and those without. In this group of 53 LOF intolerant genes in the GWAS set, enrichment was similar whether or not obese cases had developmental delay ([Figure 4](#fig4){ref-type="fig"}B; [Table S9](#mmc7){ref-type="supplementary-material"}D).

Next, we noted that the set of all 3,488 LOF intolerant genes in the genome (pLi \> 09-set) was also significantly enriched in rare variants in obesity cases (OR~*STRICT*~ = 1.07, CI~95~ = 1.02,1.13, p~perm-*strict*~ = 6.85 × 10^−3^; OR~LOF~ = 1.17, CI~95~ = 1.07,1.27, p~*perm-LOF*~ = 3.00 × 10^−4^; [Figure 4](#fig4){ref-type="fig"}A; [Table S9](#mmc7){ref-type="supplementary-material"}A). However, consistent with obesity not normally being reproductive lethal, we find most of this signal to be driven by obesity cases that also have developmental delay ([Figure 4](#fig4){ref-type="fig"}B; [Tables S9](#mmc7){ref-type="supplementary-material"}B and S9C), suggesting these genes may yield further diagnostic findings in this set of patients. In contrast, genes that are not LOF intolerant (pLi ≤ 0.9) show no evidence of enrichment ([Figures 4](#fig4){ref-type="fig"}A and 4B; [Tables S9](#mmc7){ref-type="supplementary-material"}A--S9C).

Rare Genetic Variation Associated with Obesity Is in the Most Constrained Gene Sets {#sec3.9}
-----------------------------------------------------------------------------------

Many diseases that are under strong negative selection, such as schizophrenia, have been shown to be enriched for rare, putative deleterious genetic variation in genes that are usually constrained to LOF variation (pLi \> 0.9). Given that obesity may not have undergone strong negative selection, we aimed to test whether the contribution of rare, putative deleterious genetic variation was also observed in gene sets regardless of the level of constraint against deleterious variation. To test this, we assessed gene set enrichment among the deciles of missense constrained genes where genes in the top decile are more constrained against missense variation (i.e., less likely to have missense variation in the general population) and genes in the first decile are less constrained to missense variation (i.e., more likely to have missense variation in the general population). We additionally assessed the deciles of LOF constrained genes. We did not find strong evidence of enrichment for rare deleterious variants beyond gene sets with the strongest constraint against missense or LOF variation, suggesting that, at least for extreme clinical obesity such as that studied here, enrichment for rare putative deleterious variants is primarily in genes that are strongly constrained against deleterious variation ([Table S9](#mmc7){ref-type="supplementary-material"}E).

Discussion {#sec4}
==========

Most genetic studies of obesity have to date identified very rare, likely fully penetrant monogenic mutations causal of severe forms of obesity, or common low-impact alleles influencing BMI and other measures of adiposity in large population-based cohorts. Here, by focusing our efforts on a clinical cohort of very severe early-onset obesity cases of unknown cause, and combining genetic evidence with functional work in cells and *in vivo*, we provide evidence for a continuum of causality in the genetic architecture of obesity. We identify three genes (*PHIP*, *DGKI*, and *ZMYM4*) newly implicated in obesity, harboring very rare predicted deleterious alleles, with intermediate effects and penetrance between those identified through family or large-population scale efforts.

These findings have potential diagnostic implications. While *PHIP* has previously been linked to a complex syndrome of developmental delay, and some patients have been noted to be overweight, the gene is not currently included on any gene panel for diagnostic testing in obesity, nor is *PHIP* screening recommended in obesity syndromes. The patients we identified all presented with severe obesity---some did have developmental delay, but not all. We consider that this finding plus the associated molecular work identifying a mechanism by which disruption of *PHIP* can cause obesity (by disrupting transcription of *POMC*) establishes that some patients may present with obesity alone. While we find a broad spectrum of mutations, this alone cannot explain the divergence in phenotypic spectrum seen. It is likely that as *PHIP* affects transcriptional regulation, specific mutations may exert a variable effect clinically. Our data suggest that *PHIP* should be included in genetic testing recommended in clinical guidelines as part of the assessment of severe childhood-onset obesity, particularly in the presence of developmental delay ([@bib57]). These findings may also inform the mechanism-based treatment of *PHIP* variant carriers with a melanocortin receptor agonist currently in clinical trials, which leads to significant weight loss in severe obesity due to complete POMC deficiency ([@bib29]). A subset of *PHIP* variant carriers may also benefit from treatment with recombinant leptin, leptin mimetics, or sensitizers.

Little is known of the biological function of *DGKI* or *ZMYM4*, or the mechanism through which they influence energy homeostasis. Their discovery is therefore important as it provides new avenues for future biological exploration, and establishes a new link between these genes and as yet undescribed molecular pathways implicated in human metabolism and energy homeostasis.

Our results also demonstrate the challenge in identifying novel molecular links between heterogeneous complex diseases and very rare variants that may not be fully penetrant. From a statistical standpoint, the burden of proof is high, possibly requiring in the order of tens of thousands of cases to attain established Bonferroni multiple-testing correction thresholds ([@bib68]). Nonetheless, failure to meet the stringent Bonferroni threshold does not preclude the possibility of interesting and relevant results, especially when combined with other functional evidence, which is what we have sought to do to increase confidence in our findings. This challenge has been similarly documented in other heterogeneous disorders such as autism ([@bib67], [@bib6]) and schizophrenia ([@bib56]), where single genes with a burden of rare damaging variants in cases compared to controls have also not attained the required statistical burden of proof. Nonetheless, the results of those studies have provided important insights into the genetic etiology of those disorders. Namely, in the schizophrenia study, Singh and colleagues demonstrated that a group of 3,488 genes previously shown to be intolerant to LOF mutations were enriched with a burden of rare deleterious variants in cases, identifying this group of genes as a whole as important in schizophrenia.

This result is analogous to our gene set analyses findings. We provide for the first time evidence that a group of 157 genes mapping nearest to BMI-associated GWAS loci are enriched in very rare deleterious variants in our cases. Furthermore, we demonstrate that a subset of 53 out of those 157 genes (that have evidence of being LOF intolerant genes) is even more enriched in very rare functional variants in obese cases, compared to controls achieving effect estimates similar in size to the group of well-established monogenic obesity genes. This set of 53 genes is therefore a primary target to study in more detail in future large-scale obesity sequencing studies.

Last, we demonstrate that collectively the 3,488 genes intolerant to LOF (pLi \> 0.9-set) are enriched in very rare predicted deleterious variants in severe early-onset obese patients who also have developmental delay, suggesting that further novel discoveries that are clinically relevant may be made by studying this particular subgroup of individuals and genes.

Limitations of Study {#sec4.1}
--------------------

Our study has a number of limitations. First, all the newly described genes linked to childhood obesity are driven mostly from our discovery dataset and, aside from *ZMYM4*, neither *PHIP* nor *DGKI* meet Bonferroni correction for all genes in the genome. Consequently, these findings merit replication in additional cases with severe childhood-onset obesity and also in adult obesity cases and other ancestries, to further investigate the impact of these genes in obesity more broadly. Second, while we observe enrichment of very rare predicted deleterious variants in *PHIP*, in cases with severe childhood obesity in the absence of developmental delay, this observation merits additional investigation in additional obesity cases (with and without developmental delay) to identify possible genotype-phenotype correlations. Third, the *DGKI* mouse exhibits increased fat mass only in males; further work is therefore needed to evaluate the apparent gender dimorphism, and to gain insights into the mechanism underlying the effect on body composition we observe. Overall, our results highlight the challenges in robustly linking very rare variants with incomplete penetrance to a complex and heterogeneous phenotype such as obesity.

To conclude, we demonstrate that WES in clinically ascertained severe-childhood onset obesity, and follow-up in additional unrelated cases, identifies genes and gene sets newly linked to obesity. Further investigation of the molecular mechanisms affected by rare obesity-associated variants in cells, model organisms, and humans may identify and validate potential targets for weight loss therapy.

STAR★Methods {#sec5}
============

Key Resources Table {#sec5.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Rabbit anti-PHIPProteintechCat \# 20933-1-AP; RRID: [AB_10733522](nif-antibody:AB_10733522){#interref165}Goat anti rabbit secondary antibody Alexa Fluor 488Thermo Fisher ScientificCat\# A11034; RRID: [AB_2576217](nif-antibody:AB_2576217){#interref170}Mouse anti-HA tag (6E2)Cell SignalingCat\# 2367; RRID: [AB_10691311](nif-antibody:AB_10691311){#interref175}Normal Rabbit IgGCell SignalingCat\# 2729; RRID: [AB_1031062](nif-antibody:AB_1031062){#interref180}Rabbit anti-IRS2 (L1326)Cell SignalingCat\# 3089; RRID: [AB_2125771](nif-antibody:AB_2125771){#interref185}Rabbit anti-PHIPAbcamCat\# ab86244; RRID: [AB_1925318](nif-antibody:AB_1925318){#interref190}Goat anti-rabbit IgG-HRPDakoCat\# P0448; RRID: [AB_2617138](nif-antibody:AB_2617138){#interref195}Rabbit anti-p44/42 MAPK (Erk1/2) (137F5)Cell Signaling TechnologyCat\# 4695; RRID: [AB_390779](nif-antibody:AB_390779){#interref200}Rabbit anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)Cell Signaling TechnologyCat\# 9101; RRID: [AB_331646](nif-antibody:AB_331646){#interref205}Rabbit anti-STAT3Cell Signaling TechnologyCat\# 4904; RRID: [AB_331269](nif-antibody:AB_331269){#interref210}Rabbit anti-Phospho STAT3 (pY705)Cell Signaling TechnologyCat\# 9131; RRID: [AB_331586](nif-antibody:AB_331586){#interref215}Rabbit anti-βActinCell Signaling TechnologyCat\# 4967; RRID: [AB_330288](nif-antibody:AB_330288){#interref220}**Bacterial and Virus Strains**XL10-GoldAgilentCat\# 200315**Chemicals, Peptides, and Recombinant Proteins**Lipofectamine 2000GIBCOCat\#11668FormaldehydeFisher ChemicalsF/150/PB17Triton X-100BDH306324NHuman Recombinant E.coli LeptinEMD Millipore429700Protein A SepharoseAbcamab193256DAPIInvitrogenD1306**Critical Commercial Assays**Steadylite Plus Reporter Gene Assay SystemPerkin Elmer6066759Sample-to-SNP kitThermoFisher4403081**Experimental Models: Cell Lines**HEK293ATCCCRL-1573; RRID: CVCL_0045COS7culture collection by Alan TunnacliffeN/A**Experimental Models: Organisms/Strains**Dgki (EM:11471), Zmym4 (EM:11435) and Znf32/Zfp637 (EM:11616)Infrafrontier (<https://www.infrafrontier.eu/>) or they can be obtained from WSI directly: <mouseinterest@sanger.ac.uk>EM:11471, EM:11435, EM:11616**Recombinant DNA**Human N-HA-PHIP-WT in pCDNA3.1(+) vectorThis paperN/AHuman N-HA-PHIP variants in pCDNA3.1(+) vectorThis paperN/A**Software and Algorithms**Prism 7Graph Pad Software<https://www.graphpad.com/scientific-software/prism/>WGE CRISPR tool([@bib19])N/AGATK Haplotype Caller (v3.2)([@bib10], [@bib59])<https://github.com/broadinstitute/gatk/releases>VerifyBamID (v1.0)([@bib23])<https://genome.sph.umich.edu/wiki/VerifyBamID>EIGENSTRAT v4.2([@bib50])<https://www.hsph.harvard.edu/alkes-price/software/>Meta, R package v4.9([@bib4])N/APhenStat, R package version 2.18.0([@bib30])Available from Bioconductor ([@bib15])PLINK([@bib51])<http://zzz.bwh.harvard.edu/plink/>PLINK/SEQN/A<https://atgu.mgh.harvard.edu/plinkseq/index.shtml>ProxECAT([@bib18])N/ASNPtest v2.5([@bib41])<https://mathgen.stats.ox.ac.uk/genetics_software/snptest/snptest.html>Variant Effect Predictor (VEP) version 79 with the dbNSFP plug-in (dbNSFPv2.9, Feb 3, 2015([@bib44], [@bib37], [@bib38])<http://www.ensembl.org/vep>; <https://sites.google.com/site/jpopgen/dbNSFP>SKAT, R package version 1.1([@bib31])Available from CRAN (<https://cran.r-project.org/web/packages/SKAT/index.html>)MetaSKAT, R package version 0.60([@bib32])Available from CRAN (<https://cran.r-project.org/web/packages/MetaSKAT/index.html>)

Resource Availability {#sec5.2}
---------------------

### Lead Contact {#sec5.2.1}

Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Inês Barroso (<ines.barroso@exeter.ac.uk>).

### Materials Availability {#sec5.2.2}

Plasmids generated in this study are available from the lead contact. Mouse lines generated in this study will be available from Infrafrontier (<https://www.infrafrontier.eu/>) or they can be obtained from WSI directly, <mouseinterest@sanger.ac.uk>. Dgki (EM:11471), Zmym4 (EM:11435) and Znf32/Zfp637 (EM:11616). There are currently some restrictions to the availability of mouse lines from Infrafrontier due to the patent issues surrounding CRISPR-generated mice, however these restrictions are being resolved and in the interim mouse lines are available directly from Wellcome Sanger Institute by contacting <mouseinterest@sanger.ac.uk>.

### Data and Code Availability {#sec5.2.3}

SCOOP and INTERVAL WES data are accessible from the European Genome-phenome Archive- EGA: EGAS00001000124 and EGA: EGAS00001000825, respectively. Adult obesity WES data from UK10K Generation Scotland and TwinsUK are available from EGA under accession codes EGA: EGAS00001000242 and EGA: EGAS00001000306, respectively. 1958 Birth Cohort WES data is available from the EGA under accession code EGA: EGAS00001000971. All other data are available in the manuscript or the supplementary materials.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### Human Studies {#sec5.3.1}

All studies were approved by the Cambridge Local Research Ethics Committees and all participants and their parents (for children below the age of 16) gave written informed consent. All research was conducted in line with the principles outlined in the Declaration of Helsinki.

### Samples {#sec5.3.2}

Stage 1 used whole-exome sequence data from participants in the SCOOP and INTERVAL studies (details below). Stage 2 included targeted sequence and genotype data obtained for additional SCOOP participants and participants from the FENLAND study (details below). Whole-exome sequence adult obesity data was obtained for adult obesity participants in the UK10K project ([@bib61]) and 1958 Birth Cohort participants were used as controls, but only data for four genes surviving combined stage1+stage2 analysis were analyzed.

### Childhood Obesity Cases {#sec5.3.3}

The Severe Childhood Onset Obesity Project (SCOOP) cohort ([@bib64]), includes ∼4800 British individuals of European ancestry with childhood onset obesity (BMI standard deviation score (SDS) \> 3; onset of obesity before the age of 10 years). SCOOP individuals likely to have congenital leptin deficiency, a treatable cause of severe obesity, were excluded by measurement of serum leptin, and individuals with mutations in the melanocortin 4 receptor gene (*MC4R*) (the most common genetic form of penetrant obesity) were excluded by prior Sanger sequencing. All participants had age \< 10y at the time of recruitment, sex distribution was: Female 548 (59.12%), Male 379 (40.88%).

In this study, SCOOP participants were included in stage 1 and stage 2 analyses. Stage 1 analysis comprised 982 SCOOP individuals with whole-exome sequence (WES) data obtained as part of the UK10K consortium project ([@bib61], [@bib17]). WES sequence data can be obtained from the European Genome-phenome Archive (EGA) under study accession code EGAS00001000124 ([@bib61], [@bib17]). Stage 2 analyses included 1,816 SCOOP participants selected from a total of 2,819 participants with existing sequence data on ∼1,300 genes ([@bib61]). Selection of stage 2 samples was based on: i) presence of good quality sequence data (proxy for good quality DNA); ii) European ancestry as defined by principal component analysis on off-target variants (LASER 2.0 algorithm ([@bib62]) and; iii) unrelated to SCOOP stage 1 samples. All participants had age \< 10y at the time of recruitment, sex distribution was: Female 951 (52.37%), Male 865 (47.63%).

### Adult Obesity Cases {#sec5.3.4}

WES data obtained as part of the UK10K consortium project ([@bib61]) was available for 366 Generation Scotland and 65 TwinsUK unrelated participants with BMI \> 40, and good quality sequence data. These data are available from EGA under accession codes EGA: EGAS00001000242 and EGA: EGAS00001000306. All TwinsUK participants were female, but age information was not available to us at the time of analysis. Age and sex of GS samples were not available to us at the time of analysis. The effect of age and sex was not considered in this study as our discovery study design did not allow us to investigate these parameters due to both power issues (low power for stratified analysis), and the fact that the discovery phase contrasted obese prepubertal children with age \< 10y at recruitment with control adults.

### Population Controls {#sec5.3.5}

Stage 1 analysis included 4,502 participants from the INTERVAL cohort. The INTERVAL cohort consists of 50,000 predominantly healthy blood donors in the UK ([@bib46]). All individuals were genotyped using the UK Biobank Axiom Array (Affymetrix Axiom Biobank Array) and imputed using a combined UK10K-1000G Phase 3 imputation panel ([@bib20]). A subset of 4,502 individuals were selected for whole-exome sequencing, as previously described ([@bib55]), of which 4,499 survived QC and were used as controls in this study. Information on age and sex was available to us for 4,045 of the 4,057 participants (99.70%): Age mean (SD): 43.51 (14.31); Sex Female 1,994 (49.30%), Male 2,051 (50.70%). Further details on the INTERVAL study can be obtained at <https://www.intervalstudy.org.uk/>.

Stage 2 analysis included participants from Phase 1 of the Fenland Study. The Fenland Study is a population-based cohort of 12,435 participants born between 1950 and 1975, recruited from participating General Practices from around the Cambridgeshire region in the UK. Exclusion criteria were: clinically diagnosed diabetes mellitus, inability to walk unaided, terminal illness (life expectancy of ⩽1 year at the time of recruitment), clinically diagnosed psychotic disorder, pregnancy or lactation ([@bib8]). Participants were aged 29-64 years and 53.8% were female. For the stage 2 genotyping (see below) we used 3,800 randomly selected Fenland Study participants (age range 29-64, of which sex information was available to us for 3,777 that passed QC: Female 2,040 (54.01%), Male 1,737 (45.99%)), of which a subset of 2,660 (age range 29-64, of which sex was available to us for 2,627: Female 1,392 (52.99%), Male 1,235 (47.01%)) was randomly selected for the stage 2 targeted gene sequencing (see below). Further details on the Fenland Study, including a technical summary, can be found here: <http://www.mrc-epid.cam.ac.uk/research/studies/fenland/>

Association analysis with adult obesity used 1,000 participants from the 1958 Birth Cohort as controls. The 1958 Birth Cohort Collection is a population-based collection of all individuals born in a week in 1958 in the UK (<http://www.cls.ioe.ac.uk>). Whole-exome data were obtained from EGA under accession code EGA: EGAS00001000971. Age and sex information of participants included in this study was not available at the time of analysis and was not considered in this study as our discovery study design did not allow us to investigate these parameters due to both power issues (low power for stratified analysis), and the fact that the discovery phase contrasted obese prepubertal children with age \< 10y at recruitment with control adults. Briefly, genomic DNA was used to prepare DNA libraries using the Illumina TruSeq sample preparation kit. DNA was fragmented using Covaris technology and libraries were prepared without gel size selection. Target enrichment was performed in pools of six libraries using the Illumina TruSeq Exome Enrichment kit. Captured DNA libraries were PCR amplified using the supplied paired-end PCR primers. Sequencing was performed with an Illumina HiSeq2000 (v3 flow cell, one pool per lane) generating 2x100-bp reads ([@bib40]).

gnomAD controls were the non-Finnish control exome samples (N = 21,384). GnomAD v2.1 data was downloaded on October 12, 2018 from <https://gnomad.broadinstitute.org/downloads>

### Mice {#sec5.3.6}

#### Animals, Housing and Husbandry {#sec5.3.6.1}

All mice were maintained in specific pathogen-free facilities in individually ventilated cages at standard temperature (19-23°C) and humidity (55% ± 10%), on a 12 h dark, 12 h light cycle (lights on 0730--190) and fed a breeder's chow diet (LabDiet 5021-3, 9% crude fat content, 21% kcal as fat, 0.276ppm cholesterol, LabDiet, London, UK).

All mice were given water and diet *ad libitum*, unless otherwise stated. Mice were maintained in a specific pathogen free unit on a 12 h light: 12 h dark cycle with lights off at 7:30pm and no twilight period. The ambient temperature was 21 ± 2°C and the humidity was 55 ± 10%. Mice were typically housed for phenotyping using a stocking density of 3-5 mice per cage (overall dimensions of caging: (L x W x H) 365 × 207 × 140mm, floor area 530cm^2^) in individually ventilated caging (Tecniplast Seal Safe Plus GM500) receiving 60 air changes per h. In addition to Aspen bedding substrate, standard environmental enrichment of two nestlets, a cardboard tunnel and three wooden chew blocks was provided. Mice stocking density was typically 3-5 mice per cage. The care and use of mice was performed in accordance with UK Home Office regulations, UK Animals (Scientific Procedures) Act of 1986 under a UK Home Office license (P77453634) and which were reviewed regularly by the WTSI Animal Welfare and Ethical Review Body. Animal welfare was assessed routinely for all mice involved. Mouse lines for the genes used in this study \[Dgki (EM:11471), Zmym4 (EM:11435) and Znf32/Zfp637 (EM:11616)\] can be ordered from Infrafrontier (<https://www.infrafrontier.eu/>).

#### Generation of Dgki^em1(IMPC)Wtsi^ Mutant Mice {#sec5.3.6.2}

C57BL/6N mouse zygotes were injected cytoplasmically with Cas9 mRNA (50ng/μl) from Trilink Biotechnologies and two pairs of *in vitro* transcribed gRNAs (6.25ng/μl each) flanking a critical exon. gRNAs were identified using the WGE CRISPR tool ([@bib19]) and were selected based on their off-target scores to minimize potential off target damage.SequenceChromosomeChromosome StartChromosome EndGCACTGATCCAACAATTTGGTGG63704996137049983ATATTATGGCCATATTACGGAGG63705013137050153CCTGTAGACTGTCCCAAATCCAT63705040237050424CCTGAGTAGTTCCATTAGACTTA63705066937050691

The zygotes were transferred into the oviduct of pseudopregnant females the same day of microinjection. G0 founder mosaic offspring were identified using a combination of end point PCR and gene-specific 'loss of WT allele' (LoA) qPCR assay designed to the region of the genome predicted to be deleted. G0 founder mice were mated to C57BL/6N mice to establish G1's for further breeding to C57BL/6N mice. Genomic DNA from pups produced by cytoplasmic injection of CRISPR/Cas9 reagents was isolated from an ear punch of two week old pups using the Sample-to-SNP kit (ThermoFisher, 4403081).

#### Endpoint PCR Primer Pairs and Expected Size Bands {#sec5.3.6.3}

Assay typeAssayForward PrimerReverse PrimerExpected Size Band (bp)Standard PCRWild typeDgki_DF1Dgki_ER1363Standard PCRWild typeDgki_EF1Dgki_DR1566Standard PCRMutantDgki_DF1Dgki_DR1286

Primer NamePrimer Sequence (5′ \> 3′)Dgki_DF1GTCTCCAAAATCAGACACGCADgki_EF1ACAAAAGGCATTTTTCCCACCDgki_ER1GGTACCTGAATCCACGGCAADgki_DR1ATGACATAGCCTGGCCACTT

#### LoA qPCR Primers {#sec5.3.6.4}

TargetForward Primer Seq.Reverse Primer Seq.Probe Primer Seq.*Dgki*AGATCAAAGACTTGCCGTGGATCCTTTATAGGGAACCAAAGTCCTACACAGGTACCACATAAAC

Viability of the line is assessed by genotyping a minimum of 28 offspring from heterozygous intercrosses. For *Dgki*^*em1(IMPC)Wtsi*^, this gave 23 homozygous mice from 95 offspring (Expected: 24 from 95 offspring, Fisher- exact test, p = 1.0). Mice were allocated to the pipeline randomly by Mendelian Inheritance.

#### Generation of Zmym4^em1(IMPC)Wtsi^ Mutant Mice {#sec5.3.6.5}

C57BL/6N mouse zygotes were injected cytoplasmically with Cas9 mRNA (50ng/μl) from Trilink Biotechnologies and *in vitro* transcribed gRNAs (6.25ng/μl each) flanking a critical exon. gRNAs were identified using the WGE CRISPR tool ([@bib19]) and were selected based on their off-target scores to minimize potential off target damage.SequenceChromosomeChromosome StartChromosome EndCCACTATTCGGCTAAAAGATGCA4126910579126910601CGTAATGCATGTACAGAAACTGG4126910605126910627CCACCCTCTTGGTATATTAAAGG4126911331126911353

The zygotes were transferred into the oviduct of pseudopregnant females the same day of microinjection. G0 founder mosaic offspring were identified using a combination of end point PCR and gene-specific 'loss of WT allele' (LoA) qPCR assay designed to the region of the genome predicted to be deleted. G0 founder mice were mated to C57BL/6N mice to establish G1's for further breeding to C57BL/6NTac mice. Genomic DNA from pups produced by cytoplasmic injection of CRISPR/Cas9 reagents was isolated from an ear punch of two week old pups using the Sample-to-SNP kit (ThermoFisher, 4403081).

#### Endpoint PCR Primer Pairs and Expected Size Bands {#sec5.3.6.6}

Assay typeAssayForward PrimerReverse PrimerExpected Size Band (bp)Standard PCRWild typeZmym4_DF1Zmym4_ER1274Standard PCRWild typeZmym4_EF1Zmym4_DR1531Standard PCRMutantZmym4_DF1Zmym4_DR198

Primer NamePrimer Sequence (5′ \> 3′)Zmym4_DF1CCACCACCCAGCCTAAAAGAZmym4_EF1CCCCCACAGTTCTCACAACAZmym4_ER1TCAGGGGAGTTGAAACCTTGGZmym4_DR1GGTGCTCTTACCCACTGAGC

#### LoA qPCR Primers {#sec5.3.6.7}

TargetForward Primer Seq.Reverse Primer Seq.Probe Primer Seq.*Zmym4*TGAGGTGACACACATTGAACTACAACAGTGCCATGTGCTGCAAATACTTCTTAGACTGCCCCTC

Viability of the line is assessed by genotyping a minimum of 28 offspring from heterozygous intercrosses. For *Zmym4*^*em1(IMPC)Wtsi*^ this gave 0 homozygous mice from 56 offspring (Expected: 14 from 56 offspring, Fisher- exact test, p \< 0.0001).

#### Primary Standardized Phenotyping Pipeline {#sec5.3.6.8}

Mice underwent primary standardized phenotyping from 4 weeks of age and had only previously undergone earclip biopsies to identify the mice and establish genotype before entering the pipeline. Mice were randomly assigned to cohorts by Mendelian inheritance by colony managers that were separate from the team performing the phenotyping. *Dgki* homozygous mutant mice on the C57BL/6NTac background were tested in 7 batches (2 batches of 2 females each, 1 batch of 1 male, 1 batch of 1 female, 1 batch of 2 females and 1 male, 1 batch of 2 males and 1 batch of 3 males). All 14 *Dgki* mutant mice completed the pipeline without loss due to welfare or health concerns. No health concerns or adverse effects were noted during or outside of procedures. With each batch of mutant mice, a cohort of typically 7 age and sex matched (though not littermate) wild-type C57BL/6NTac mice were also phenotyped, to provide longitudinal control values as described in the [Quantification and Statistical Analysis](#sec5.5){ref-type="sec"} section. Key phenotyping results are shown in [Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}. Data collected include weight curves, basic behavioral/morphological assessment at 9 weeks of age, intraperitoneal glucose tolerance test (ipGTT) at 13 weeks and body composition assessment by dual emission X-ray absorptiometry (DEXA) at 14 weeks of age using a modified version of the MGP pipeline detailed previously ([@bib65]), using a mouse breeder's chow (LabDiets 5021, 9% crude fat content, 21% kcal as fat, 0.276ppm cholesterol, LabDiet, London, UK) instead of a high fat diet. At 16 weeks, random-fed mice were anesthetized using 100 mg/kg Ketamine and 10 mg/kg Xylazine and blood was collected retroorbitally. Samples were used to measure total blood counts, clinical chemistry parameters and for analysis by flow cytometry. Death was confirmed by cervical dislocation and heart removal. As a high throughput screen where genes are selected for study without hypothesis and mice are studied in multiple batches and alongside mice with mutations for different genes, there is limited room for personal bias to influence the results. For mouse management purposes, the cages have both genotype and allele information and hence the intraperitoneal glucose tolerance test (ipGTT) and Dual-energy X-ray absorptiometry (DEXA) screens are run unblinded. Basic behavioral/morphological assessments were run with the technician blinded to the specific allele of the mouse, but not whether the mouse was wild type or a mutant. Necropsies of mice were performed by staff blinded to genotype and allele. Analysis of blood samples for clinical chemistry were run blind using a barcode system. Typically, necropsies and blood collections are performed from 9am-12pm, fasting for GTT starts 9am with the sample collection beginning at 1pm. DEXA and behavioral analysis could be performed at any time between 9am and 4pm. The order of cages and mice treated and assessed in any given procedure was not predetermined. All data was collected using a bespoke mouse and data management system to allow QC of data under predefined conditions, and data was only analyzed once all data from that line had been collected. The standard operating procedures can be found at IMPReSS (<https://www.mousephenotype.org/impress>).

Dual-energy X-ray absorptiometry: DEXA was performed using an Ultrafocus 100 (Faxitron Bioptics LLC, Tuscon, Arizona, USA) under isofluorane anesthesia (IsoFlo, Zoetis UK Ltd., London, UK), in order to minimize recovery times while immobilizing the mouse for data collection. Nose to tail base length measurements were performed using a ruler with 1mm graduations prior to DEXA measurement. Parameters measured included fat mass (g), fat percentage estimate (%), lean mass (g), bone mineral density (mg/cm^2^), and bone mineral content (g). Internal calibration was performed prior to any imaging.

Intraperitoneal Glucose tolerance test: Mice were single-housed and fasted for 4 h. Approximately 0.5mm of the tail tip was removed with a scalpel blade and a fasting blood sample (T0) was directly taken (Accu-chek Aviva, Roche, Indianapolis, IN). Mice were then injected with 2g/kg glucose intraperitoneally and further blood samples were taken at 15 (T15), 30 (T30), 60 (T60) and 120 (T120) minutes post-glucose injection. Area under the curve (AUC) was calculated using the trapezoid method, where glucose at T0 was used as the baseline value for the mouse. Two female and one male homozygous mice had their T15 to T120 data removed from analysis due to glucose injection failures.

Clinical Chemistry (CC): Blood was collected from animals in the random-fed state between 08:30 and 10:30. Mice were anesthetized using 100 mg/kg Ketamine and 10 mg/kg Xylazine and blood was collected into heparinized pediatric tubes (Kabe Labortechnik GmbH, Numbrecht, Germany) using the retro-orbital route, followed by heart removal and cervical dislocation. This anesthesia/administration combination allowed the collection of a sufficient amount of non-hemolyzed blood, particularly for electrolyte parameters that may be strongly affected by hemolysis. Heparinized whole-blood samples were centrifuged at 5,000 rcf for 10 min at 4°C, and the plasma was collected and stored at 4°C until analysis, always within 1 h of collection. Plasma variables were assessed at room temperature using an AU480 chemistry analyzer (Beckman Coulter, High Wycombe, UK). Glucose levels were not analyzed from the clinical chemistry screen due to the rapid increase in plasma glucose under Ketamine/Xylazine based anesthesia.

Method Details {#sec5.4}
--------------

### Cell Culture {#sec5.4.1}

HEK293 (XX female) cells were cultured in high glucose Dulbecco's modified eagle medium (DMEM, GIBCO, 41965) supplemented with 10% fetal bovine serum (GIBCO, 10270, South America origin), 1% GlutaMAX (100X) (GIBCO, 35050), and 100 units/mL penicillin and 100 μg/mL streptomycin (Sigma-Aldrich, P0781) at 37°C, 5% CO2. COS-7 (XY male) cells were cultured in low glucose Dulbecco's modified Eagle's medium (Sigma, D6046) supplemented with 10% fetal bovine serum, 1% GlutaMAX, 100 IU/mL penicillin and 100 ng/mL streptomycin at 37°C, 5% CO2.

### Cloning of PHIP Human Variants {#sec5.4.2}

PHIP cDNA constructs containing an N-terminal HA tag in pCDNA3.1 (+) vector (Invitrogen) were used throughout the study ([NM_017934.7](ncbi-n:NM_017934.7){#interref225}). Site-directed mutagenesis was performed using Q5 site-directed mutagenesis kit (NEB, E0554S) according to the manufacturer's protocols. All constructs were verified with Sanger sequencing.

### Subcellular Localization of Endogenous PHIP {#sec5.4.3}

COS-7 cells were seeded in black clear bottom CellCarrier-96 Ultra Microplates (Perkin Elmer, 6055302) coated with Poly-D-Lysine solution (Sigma, A-003-E) (20.000 cells/well). After 24 h, cells were fixed with 4% Formaldehyde (Fisher Chemicals, F/150/PB17) in Phosphate-buffered saline (PBS) for 20 min at room temperature, permeabilized with 0.2% Triton X-100 (BDH, 306324N) for 30 min at room temperature, blocked for 1 h in 3% Bovine Serum Albumine (BSA) (Sigma, A7906) at room temperature, and incubated overnight at 4°C with Rabbit anti-PHIP (Proteintech, 20933-1-AP) in 1:100 dilution in 3% BSA or without antibody as a negative control. Cells were washed three times with PBS for 5 min, incubated with goat anti rabbit secondary antibody Alexa Fluor 488 (Thermo Fisher Scientific, A11034) in 1:200 dilution in 3% BSA for 1 h at room temperature, washed 2 times with PBS for 5 min, incubated with DAPI (Invitrogen, D1306) in 1:500 dilution in PBS for 10 min and kept in PBS. Cells were imaged in the Opera Phenix High Content Screening Confocal system (Perkin Elmer).

### Luciferase POMC Transcription Activation Assay {#sec5.4.4}

HEK293 cells were seeded into white 96-well plates coated with Poly-D-Lysine (40,000 cells/well) and transiently transfected the next day with 100ng/well plasmid encoding either empty pcDNA3.1(+) vector (negative control), WT or mutant PHIP plasmid, combined with 50ng/well plasmid for Leptin Receptor, 50ng/well plasmid for POMC luciferase and 10ng/well plasmid for STAT3 using Lipofectamine 2000 (Thermo Fisher Scientific, 11668019) in serum-free Opti-MEM I medium (GIBCO, 31985) according to the manufacturer's protocols. After 6 h transfection media was replaced by full DMEM. The next day cells were incubated overnight with starvation media (DMEM no FBS) with or without the presence of 200ng/mL Leptin (Human Recombinant E.coli, EMD Millipore, 429700). Quantitation of firefly luciferase activity was performed using the Steadylite Plus Reporter Gene Assay System (Perkin Elmer, 6066759) according to the manufacturer's protocol.

### Dominant Negative Luciferase POMC Transcription Activation Assay {#sec5.4.5}

HEK293 cells were seeded in white 96-well plates coated with Poly-D-Lysine (40,000 cells/well) and transiently transfected the next day with 50ng/well plasmid encoding empty pcDNA3.1(+) vector together with 50ng/well WT PHIP plasmid or 50ng/well WT PHIP plasmid together with different concentrations of mutant PHIP plasmid and combined with 50ng/well plasmid for Leptin Receptor, 50ng/well plasmid for POMC luciferase and 10ng/well plasmid for STAT3 using Lipofectamine 2000 in Opti-MEM I medium according to the manufacturer's protocols. After 6 h, transfection media was replaced by full DMEM. The next day cells were incubated overnight with starvation media (DMEM no FBS) with or without the presence of 200ng/mL Leptin. Quantitation of firefly luciferase activity was performed using the Steadylite Plus Reporter Gene Assay System (Perkin Elmer, 6066759) according to the manufacturer's protocol.

### Subcellular Localization of Human PHIP Variants {#sec5.4.6}

COS-7 cells were seeded into black clear bottom CellCarrier-96 Ultra Microplates coated with Poly-D-Lysine (20.000 cells/well) or into glass coverslips in 12-well plates coated with Poly-D-Lysine (150.000 cells/well). Cells were transiently transfected with 100ng/well plasmid encoding either empty pcDNA3.1(+) vector (negative control), WT or mutant PHIP plasmid, combined with 50ng/well plasmid for Leptin Receptor, and 10ng/well plasmid for STAT3 using Lipofectamine 2000 in Opti-MEM I medium according to the manufacturer's protocols. After 6 h, transfection media was replaced by full DMEM. The next day cells were incubated overnight with starvation media and stimulated with 200ng/mL Leptin for 10 min. Cells were immediately fixed with 4% Formaldehyde in PBS for 20 min at room temperature, permeabilized with 0.2% Triton X-100 for 30 min at room temperature, blocked for 1 h in 3% BSA at room temperature and incubated overnight at 4°C with Mouse anti-HA tag (6E2) (Cell Signaling, 2367) in 1:100 dilution in 3% BSA. Cells were washed three times with PBS for 5 min, incubated with goat anti mouse secondary antibody Alexa Fluor 488 in 1:200 dilution in 3% BSA for 1 h at room temperature, washed 2 times with PBS for 5 min, incubated with DAPI in 1:500 dilution in PBS for 10 min and kept in PBS. Cells in the 96 well plates were imaged in the Opera Phenix High Content Screening Confocal system, obtaining 9 images per well. Quantification of nuclear and cytoplasmic localization was performed with the Harmony software (Perkin Elmer) using the Alexa 488 signal and nucleus to cytoplasm ratio was calculated by dividing the number of cells/well with positive signal in the nucleus (normalized to total number of cells in the well) to the number of cells/well with positive signal in the cytoplasm (normalized to total number of cells in the well). Slides were imaged using a Leica SP8 confocal microscope (Leica Microsystems). In both experiments images were processed using FIJI.

### *In Vitro* Immunoprecipitation Assay {#sec5.4.7}

HEK293 cells stably expressing the leptin receptor were seeded in 10cm cell culture dishes coated with Poly-D-Lysine (500.000 cells/well). Cells were starved overnight, stimulated with 200ng/mL insulin (Sigma, i9278) or leptin for 15 min and lysed with cell lysis buffer containing 50 mM Tris, 50 mM KCL, 10 mM EDTA, 1% NP-40, supplied with protease inhibitor cocktail (Roche cOmplete, Mini Protease Inhibitor Cocktail, 11836153001) and phosphatase inhibitor cocktail A (Roche PhosSTOP, PHOSS-RO). Samples were sonicated 30seconds on/60 s off for 4 times at 4°C using the Diagenode Bioruptor+ (Diagenode) and collected by centrifugation at 14000 rpm for 20 min at 4oC. An aliquot was kept as input and the rest was aliquoted in comparable amounts of protein (1mg/sample) and incubated with 20μl per sample of Protein Beads A (Protein A Sepharose, Abcam, ab193256) for 2 h at 4°C (pre-clean up). Samples were span at 800rpm for 30 s and incubated overnight with 5μl of normal Rabbit IgG (Cell Signaling, 2729) or Rabbit anti-IRS2 (L1326) (Cell Signaling, 3089). The next day Protein Beads A were blocked with 5% BSA and 1% NP40 for 2 h at 4°C, incubated with the sample and antibody mix for 3 h at 4°C and washed 4 times with Tris-buffered saline (TBS) supplemented with 0.1% Tween 20 (TBS-T) at room temperature. Beads were eluted in 20μl PBS, 3μl Bolt reducing agent (Thermo, B0009) and 7μl Bolt LDS sample buffer (Thermo, B0007) for 10 min at room temperature followed by 10 min at 95°C and final centrifugation for 2.5 min at 8000 rpm. For the input 20μl per sample were resuspended in Bolt LDS sample buffer and Bolt reducing agent and heated for 10 min at 95°C. Equal volume of samples were loaded and protein electrophoresis was performed using Bolt 4%--12% Bis-Tris Plus gels (Thermo, NW04125BOX) and transferred onto nitrocellulose membrane using an iBLOT (Thermo, IB301001). After blocking with 5% milk solution in TBS-T for 1 h at room temperature, membranes were probed overnight at 4°C using Rabbit anti-PHIP (Abcam, ab86244) at 1:200 dilution in 5% milk in TBS-T. Cells were washed three times with TBS-T for 10 min at room temperature with gentle shaking and incubated with secondary antibody, Goat anti-rabbit IgG-HRP (Dako, P0448) diluted 1:2000 in 5% milk in TBS-T for 1 h at room temperature. Bands were developed using enhanced chemiluminescence (ECL) substrate (Promega, W1015) and images were captured with an ImageQuant LAS 4000 (GE Healthcare). The band intensity of western blots was quantified using FIJI.

### Western Blotting {#sec5.4.8}

HEK293 cells stably expressing the leptin receptor were seeded in 6 well plates coated with Poly-D-Lysine (50.000 cells/well). Cells were starved overnight, stimulated with 200ng/mL leptin for indicated periods of time and lysed in radio-immunoprecipitation assay buffer (RIPA) (Sigma, R0278) supplemented with protease and phosphatase inhibitors. Cells were harvested by centrifugation at 14.000 rpm for 30 min and prepared for electrophoresis as described previously. Membranes were blocked with 5% BSA solution in TBS-T for 1 h at room temperature and probed overnight at 4°C using Rabbit anti-p44/42 MAPK (Erk1/2) (137F5) at 1:1000 dilution (Cell Signaling Technology, 4695), Rabbit anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) at 1:1000 dilution (Cell Signaling Technology, 9101), Rabbit anti-STAT3 at 1:1000 dilution (Cell Signaling Technology, 4904), Rabbit anti-Phospho STAT3 (pY705) (Cell Signaling Technology, 9131) at 1:1000 dilution, Rabbit anti-PHIP at 1:1000 dilution (Proteintech, 20933-1-AP) and Rabbit anti-βActin (Cell Signaling Technology, 4967) at 1:5000 dilution all prepared in the blocking buffer. Cells were washed three times with TBS-T for 10 min at room temperature with gentle shaking and were incubated with secondary antibody, Goat anti-rabbit IgG-HRP (Dako, P0448) diluted 1:2000 in 5% BSA in TBS-T for 1 h at room temperature. Bands were developed as described previously.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

### Sequencing {#sec5.5.1}

All genetic data were on build GRCh37 coordinates.

### Stage 1 Data {#sec5.5.2}

Stage 1 analysis included existing sequence data generated as part of other whole-exome sequencing efforts (details below).

#### Sequencing and Variant QC {#sec5.5.2.1}

Details of sequencing and variant calling for the SCOOP cases, as part of the UK10K exomes, and INTERVAL controls can be found elsewhere ([@bib18], [@bib61], [@bib55]). Briefly, single--sample variant calling using GATK Haplotype Caller (v3.2) was performed on the union of Agilent v3 and v5 targets plus a 100 base pair flanking region on 9,795 UK10K and INTERVAL samples, including SCOOP cases (N = 982) and INTERVAL controls (N = 4,499). The called variants were then merged into 200 sample batches and were joint-called using GenotypeVCFs and default settings ([@bib10], [@bib59]). To ensure high-quality variant calls across all datasets and sequencing batches, only variants with at least 7x coverage in at least 80% of samples were called. We applied further variant QC keeping only variants with a calibrated VQSR tranche above 99.75% sensitivity, missingness \< 20%, Hardy-Weinberg equilibrium χ2 p value \> 10E-8, mean genotype quality ≥ 30, and variants in low-complexity regions as described here ([@bib35]). Further, individual genotypes were set to missing if any of the following were true: GQ \< 30, alternate allele read depth (DP1)\<2, allelic balance (AB, proportion of reads supporting one of the alleles of the genotype) \< 0.2, or AB \> 0.8.

#### Sample QC {#sec5.5.2.2}

We used VerifyBamID (v1.0) ([@bib23]) and a threshold of ≥ 3% to identify contaminated samples, principal components calculated from the 1000Genomes Phase I integrated call set ([@bib1]) using EIGENSTRAT v4.2 ([@bib50]) to identify non-Europeans, and pairwise identity by descent estimates from PLINK v1.07 ([@bib51]) with a threshold of ≥ 0.125 to identify related individuals. We also removed samples with a mean read depth lower than 12. This process resulted in 927 SCOOP cases and 4,057 INTERVAL controls for stage 1 analysis. Among these 927 SCOOP cases, 226 were diagnosed with developmental delay in addition to obesity.

### Stage 2 Data {#sec5.5.3}

Stage 2 data included targeted sequencing data generated within this study and obtained from additional cases and controls, unrelated to stage 1 cases and controls.

#### Targeted Sequencing and Variant QC {#sec5.5.3.1}

Targeted sequencing was performed at the Wellcome Sanger Institute (WTSI). DNA samples (300ng), genomic (Fenland) or whole-genome amplified (SCOOP), were pooled in up to 384 uniquely indexed paired-end libraries using the Illumina TruSeq Custom Amplicon Library Preparation Kit according to the manufacturer's instructions, ensuring a mix of SCOOP and Fenland samples in each 384-well pool. Amplicons (in the range 220bp-280bp) were designed using Illumina's tool DesignStudio, to cover exons, UTRs and intron/exon boundaries of the 9 genes of interest, based on UCSC hg19. In total, 146 target regions were covered. Sequencing was performed using 384-plexing and paired-end 300 cycles on Illumina MiSeq v2 to give bi-directional coverage of all amplicons.

Data were aligned to the 1000 Genomes Project Phase 2 GRCh37 human reference genome sequence (hs37d5). The CRAM files produced from these alignments were converted to BAM format, *removing* duplicate flagging (SamTools v1.3 and BioBamBam2 v2.0.65). Variant calling was performed using Genome Analysis Toolkit (GATK) v3.6 HaplotypeCaller to call germline SNPs and indels via local re-assembly of haplotypes, and GenotypeGVCFs to perform joint genotyping on all samples together. Variants were annotated with the NCBI dbSNP database build 149, limiting to target regions ± 100bp.

Genotypes were set to missing if their depth was lower than 15, or if their genotype quality (GQ) was lower than 20 for SNPs and lower than 60 for indels. For heterozygous genotypes, we further considered the allele balance (AB). Heterozygous genotypes with AB outside of \[15% - 85%\] range were set to missing. Heterozygous genotypes with moderate AB in the ranges of \[15% - 35%\] or \[65%--85%\] were required to have a depth greater than 25, otherwise the genotype was set to missing. Indels genotypes with depth greater than 2000 were also set to missing.

Variants were removed as part of the quality control process if: i) they mapped more than 100bp away from of any target region; ii) call rate was lower than 90% among cases or among controls; iii) difference in call rates between cases and controls was greater than 2.5%; iv) they failed any GATK hard filtering (QualByDepth \> 2 ; FisherStrand \> 60 for SNPs or \> 200 for indels ; RMSMappingQuality \< 40 for SNPs or \< 10 for indels; MappingQualityRankSumTest \< −12.5; ReadPosRankSumTest \< −8 for SNPs or \< −20 for indels; StrandOddsRatio \> 3.0 for SNPs or \> 10.0 for indels); v) window size for filtering adjacent gaps (GapWin) was lower than 3; vi) within 5bp around a gap to be filtered (SnpGap, for SNP). This process led to 858 variants of good quality in the 9 genes of interest.

#### Sample QC {#sec5.5.3.2}

Of the 1,816 SCOOP samples sequenced five had a missing rate greater than 15% and one had a mean depth below 12. Those six samples were excluded, leaving 1,810 SCOOP cases for downstream analyses. Following the same process, 10 FENLAND samples were excluded for having a missing rate greater than 15%, and three a mean depth below 12. This left 2,647 FENLAND controls for stage 2 analysis.

### Validation Sanger Sequencing {#sec5.5.4}

Sanger sequencing was performed to validate singleton and doubleton variants identified in stage 1 and stage 2 analyses from genes with promising results (details below). Briefly, customized PCR primers were designed ± 250 bp surrounding the variant; sequencing was performed using BigDye Terminator v3 kit (Applied BioSystems) and analyzed by capillary electrophoresis on an ABI3730 DNA Analyzer platform (Applied Biosystems), according to the manufacturers' instructions. Familial segregation analysis of variants was performed where family samples were available and where family members consented to genetic studies. In total 42 singleton/ doubleton variants (48 genotypes) identified by LOF and STRICT analysis in stage 1 analysis were validated by Sanger sequencing in the original cases and controls. All variants confirmed and all 9 genes were taken for stage 2 targeted sequencing. As targeted sequencing was done on genome-amplified case DNA, 19 variants from cases from stage 2 analysis in four genes (*DGKI*, *PHIP*, *ZMYM4* and *ZNF32*) with promising stage 1+2 LOF and STRICT results ([Table S6](#mmc5){ref-type="supplementary-material"}) were taken for sequence validation, of which 13 confirmed. Stage 2 variants seen in controls in the same four genes were also taken for validation: 9 variants were confirmed and 1 doubleton variant was not ([Table S6](#mmc5){ref-type="supplementary-material"}B). Final meta-analysis results of stage 1+ stage 2 validated variants are shown in [Table 1](#tbl1){ref-type="table"}.

### Adult Obesity Cases and 1958BC Data {#sec5.5.5}

Although data were available exome-wide, we only performed lookup of data for four genes that had survived our combined stage1+2 childhood obesity analysis.

#### Joint Calling, Sequencing and Variant QC {#sec5.5.5.1}

BAM files from the 1958 Birth Cohort and the Adult obesity cases were converted into gVCF format files using HaplotypeCaller version 3.2-2-gec30cee of the Genome Analysis Toolkit (GATK) from the Broad Institute. The regions processed using HaplotyeCaller were restricted to the intersection of the Aigilent V3 and Illumina TruSeq baits, plus 100bp padding at both 3′ and 5′ ends of the baits. The resulting gVCF files were combined in batches of 200 into multi-sample gVCF files using the GATK tool CombineGVCFs. These multi-sample gVCFs were in turn further combined and variants called using the GATK tool GenotypeGVCFs so as to produce a single VCF file containing the genotypes of all the samples included in the study. Quality scores for SNPs described in the VCF file were improved by running GATK VariantRecalibrator, and subsequently applying these scores to the VCF file using GATK ApplyRecalibration.

Variants were removed as part of the quality control process if: i) call rate was lower than 90% among Generation Scotland cases or among TwinsUK cases or among controls; ii) difference in call rates in at least one of the three comparisons was greater than 2.5% (Generation Scotland cases versus TwinsUK cases or Generation Scotland cases versus controls or TwinsUK cases versus controls); iii) they failed any GATK hard filtering available (QualByDepth \> 2 ; FisherStrand \> 60 for SNPs or \> 200 for indels ; RMSMappingQuality \< 40 for SNPs or \< 10 for indels; MappingQualityRankSumTest \< −12.5; ReadPosRankSumTest \< −8 for SNPs or \< −20 for indels); iv) window size for filtering adjacent gaps (GapWin) was lower than 3; v) within 5bp around a gap to be filtered (SnpGap, for SNP). This process led to 1,128,931 exome-wide variants of good quality.

#### Sample QC {#sec5.5.5.2}

Sample quality control was done across good quality variants. We identified one control sample with a missing rate greater than 5%; 13 control samples showing outlier relatedness values with most of the cases and controls, pointing to potential contamination; and two control samples being non-European, based on the principal component analysis. No cases were further excluded. This left 431 adult obesity cases and 984 control samples for analysis.

### Variant Annotation {#sec5.5.6}

Variant frequency was annotated with respect to the UK10K-cohort reference panel and each of the four global populations in the 1000 Genomes Phase 1 reference panel: African population (YRI, LWK, ASW), American population (MXL, CLM, PUR), Asian population (CHB, CHS, JPT) and European population (CEU, TSI, FIN, GBR, IBS). Variants were annotated for functional consequences and damaging scores using the Ensembl Variant Effect Predictor (VEP) version 79 with the dbNSFP plug-in (dbNSFPv2.9, Feb 3, 2015) ([@bib44], [@bib37], [@bib38]). Allelic changes were defined as loss-of-function (LOF analysis, see below) if the VEP consequence in protein-coding transcripts was among splice_donor_variant, splice_acceptor_variant, stop_gained, frameshift_variant. For allelic changes annotated as missense (VEP consequence in protein-coding transcripts), we further considered five tools available in dbNSFP to classify the change as damaging: SIFT prediction "damaging," PolyPhen2 HDIV predictions "probably damaging" and "possibly damaging," PolyPhen2 HVAR predictions "probably damaging" and "possibly damaging," LRT prediction "deleterious," and MutationTaster prediction "disease causing automatic" or "disease causing." Allelic changes were defined as strictly damaging (STRICT analysis, see below) if the VEP consequence in protein-coding transcripts was LOF as defined above or stop_lost or initiator_codon_variant or missense classified as damaging by all 5 prediction tools: this category aims to identify allelic changes that are likely to be damaging. Allelic changes were defined as broadly damaging (BROAD analysis, see below) if it was strictly damaging or missense classified as damaging by at least one of the 5 prediction tools: this category aims to discard allelic changes that are likely to be benign.

### Single-variant Association Analyses {#sec5.5.7}

#### Stage 1 and Stage 2 Analyses {#sec5.5.7.1}

Case-control association analysis was performed using SNPtest v2.5 with the -newml option, which implements a likelihood ratio test. Analyses were done unadjusted for age and sex because of insufficient power for stratified analysis and, since all obese participants were prepubertal with age \< 10yr at recruitment, the study was not designed to address the effect of age or sex. In stage 1, single-variant analysis was performed on all variants regardless of minor allele count (MAC) or imputation quality. Forty-seven variants with p value \< 10^−4^ and with case MAF \> control MAF ([Table S1](#mmc2){ref-type="supplementary-material"}), as well as an additional 14 variants driving gene-based analyses (based on 10 genes from BROAD analysis) were prioritized for stage 2 follow-up ([Figure S1](#mmc1){ref-type="supplementary-material"}; [Table S2](#mmc3){ref-type="supplementary-material"}C). After LD pruning using PLINK (parameters:--clump-p1 0.0001--clump-p2 0.2--clump-r2 0.5--clump-kb 500), 53 variants remained. Of these, five variants failed assay design resulting in 48 variants that were assayed on the stage 2 samples. Four SNPs were removed due to having a call rate below 80% in either SCOOP cases or Fenland controls resulting in 44 SNPs for analysis in stage 2.

#### Stage1+2 Meta-Analysis {#sec5.5.7.2}

Fixed-effects meta-analysis, combining the original and replication samples, was performed using the R package Meta and function *metagen*. No single variant passed single-variant genome-wide significance threshold (p value \< 5x10^−8^) after meta-analysis ([Table S5](#mmc4){ref-type="supplementary-material"}).

### Gene-based Association Analyses {#sec5.5.8}

#### Stage 1, Stage 2 and Adult Obesity versus Controls {#sec5.5.8.1}

Gene-based association analyses were performed using a nested approach considering three gene-burden tests filtering for variants with different MAF and with different *in silico* variant function predictions. Analyses were done unadjusted for age and sex because of insufficient power for stratified analysis and, since all obese participants were prepubertal with age \< 10yr at recruitment, the study was not designed to address the effect of age or sex. Manhattan and QQ plots for the three gene-burden tests are shown in [Figure S2](#mmc1){ref-type="supplementary-material"}. The same approach was used in stage 1 (SCOOP versus INTERVAL, [Table S2](#mmc3){ref-type="supplementary-material"}), stage 2 (SCOOP versus FENLAND, [Table S6](#mmc5){ref-type="supplementary-material"}), and adult obesity (Generation Scotland & TwinsUK versus 1958BC, [Table S4](#mmc1){ref-type="supplementary-material"}).

Rare alleles were defined as alleles having a frequency lower than 1% in each of the four 1000G populations and in the UK10K-Cohort reference panel, and also in at least one of the analysis groups. Namely, for stage 1 analysis, we required the alleles to be rare (\< 1%) across 4,057 INTERVAL control samples, or rare across the 927 SCOOP samples, or rare across the 431 adult obesity cases. For stage 2, we required the allele to be rare (\< 1%) across 2,647 FENLAND controls, or rare across 1,810 SCOOP samples. For adult obesity versus 1958BC, we required the allele to be rare (\< 1%) across 984 1958BC controls, or rare across 431 adult obesity samples.

Similar to rare allele definition, very rare alleles were defined as alleles having a frequency lower than 0.025% in each of the four 1000G populations and in the UK10K-Cohort reference panel, and also in at least one of the analysis group. The MAF \< 0.025% was chosen to focus on variants likely to be private to any given family or clan, and avoid definitions based on "not seen in public databases" which change over time.

We performed three nested gene-burden tests. 1- The LOF analysis considered variants with very rare alleles (MAF \< 0.025%) for which the change was categorized as being LOF as described above: 6,160 genes with at least 2 variants were analyzed. 2- The STRICT analysis considered variants with very rare alleles (MAF \< 0.025%) for which the variants were classified as having a deleterious effect by five *in silico* prediction programmes as described above: 13,496 genes with at least 2 variants were analyzed. 3- The BROAD analysis considered variants with rare alleles (MAF \< 1%) for which the change was categorized as broadly damaging as described above: 17,885 genes with at least 2 variants were analyzed.

Gene-based analyses were performed using the *SKATBinary* function from the R package SKAT (version 1.1. 4, April 1, 2016) ([@bib31]). The p values were computed without adjustment (method.bin = "UA"). LOF and STRICT analyses were performed using the burden test implemented in *SKATBinary* (method = "Burden"), while the BROAD analysis (rare and broadly damaging allelic changes) was performed using SKAT-O (method = "SKATO"). All other *SKATBinary* options were set to their default value. Stage 1 yielded seven genes based on LOF and STRICT analysis with OR \> 1 and p value \< 10^−4^ ([Table S2](#mmc3){ref-type="supplementary-material"}), which were selected for stage 2 targeted sequencing. In addition, BROAD analysis yielded 10 genes with OR \> 1 and p value \< 10^−4^ ([Table S2](#mmc3){ref-type="supplementary-material"}), of 10 genes, 8 genes were driven by 12 variants based on leave-one-out analysis (see below) and 2 genes were influenced by 2 variants, but signal remained after leave-one-out analysis so were also taken for stage 2 targeted sequencing ([Table S2](#mmc3){ref-type="supplementary-material"}; [Figures S1](#mmc1){ref-type="supplementary-material"} and [1](#fig1){ref-type="fig"}).

#### Leave-one-out Analyses {#sec5.5.8.2}

To identify gene-based results driven by one or more variants, we applied the following leave-one-out strategy: 1- among the variants seen more than twice in our stage 1 sample (cases and controls together), we identified the variant with the lowest single-variant analysis p value whenever it is nominally significant (p \< 0.05); 2- we removed this variant and performed the stage 1 gene-based test again. We repeated steps 1 and 2 until the stage 1 gene-based p value was above 0.1 or there were no additional variants seen more than twice and with a single-variant analysis p value \< 0.05. For genes that were driven by one or two single variants (8 genes, [Table S2](#mmc3){ref-type="supplementary-material"}; [Figure S1](#mmc1){ref-type="supplementary-material"}), we genotyped single variants. Otherwise, we sequenced the coding region of the gene.

#### Stage1+2 Meta-Analyses {#sec5.5.8.3}

Gene-based meta-analysis was performed for 9 genes selected from stage 1 analysis and taken forward for targeted sequencing in stage 2. This analysis was performed using the *MetaSKAT_wZ* function from the R package MetaSKAT (version 0.60, August 17, 2015) ([@bib32]). For the LOF and STRICT analyses, we use the option r.corr = 1 to run a burden test, while for broad analysis, we used the option method = "optimal" to run SKAT-O. All other *MetaSKAT_wZ* options were set to their default value.

#### Association Analysis Using External Controls {#sec5.5.8.4}

We used ProxECAT ([@bib18]), to perform case-control analysis of the burden of LOF and STRICT very rare variants in the gene region for 927 SCOOP cases versus 21,384 external common controls of non-Finnish European descent from gnomAD. ProxECAT tests for a difference in the ratio of very rare functional variants (LOF or STRICT) to very rare synonymous variants between cases and controls. Comparing the ratio of functional to synonymous variants enables the inclusion of external controls, but can reduce power to detect an association. As this analysis uses the same set of cases from the stage 1 analysis, it is not a true replication, but can provide more evidence for or against an association given the different control sample. This can be especially helpful for genes where there were no rare minor alleles identified in the controls from the stage 1 analysis (i.e., STRICT: *ZNF32*, *HEPACAM*; LOF: *ZMYM4, PHIP, VIL1*) ([Table S3](#mmc1){ref-type="supplementary-material"}).

### Genotyping {#sec5.5.9}

Based on results from the stage 1 single-point analysis (47 variants, see below) and gene-based tests (14 variants, see below) ([Figure S1](#mmc1){ref-type="supplementary-material"}), 53 variants were selected to take forward to stage 2 in an additional 1,810 SCOOP and 3,800 randomly-selected Fenland samples. Of the 53 variants, 48 assays were successfully designed for Agena genotyping (Agena Bioscience) across 2 plexes. Four SNPs failed QC resulting in 44 SNPs for single variant analysis. Sixty-two SCOOP cases and 23 Fenland controls with a call rate below 0.9 were removed, resulting in 1,754 SCOOP cases and 3,777 Fenland controls for single-variant analysis in the stage 2 dataset.

### Gene Set Enrichment {#sec5.5.10}

A summary of gene sets used is in [Table S8](#mmc6){ref-type="supplementary-material"}.

### Gene Sets {#sec5.5.11}

#### Obesity and Syndromic Obesity Gene Set {#sec5.5.11.1}

Genes known to harbor causal, highly penetrant mutations involved in human obesity were taken from Table 1 in [@bib48] ([Tables S8](#mmc6){ref-type="supplementary-material"}A and S8B).

#### Developmental Disorder Gene2Phenotype Gene Set {#sec5.5.11.2}

The Developmental Disorder Gene2Phenotype (DDG2P) online system curates genes related to developmental delay and the strength of evidence for the association between the gene and developmental delay. More details can be found here: <https://www.ebi.ac.uk/gene2phenotype>. DDG2P gene annotation from July 23, 2017 was used for analysis ([Tables S8](#mmc6){ref-type="supplementary-material"}B and S8C).

#### Constrained and Unconstrained Gene Set {#sec5.5.11.3}

All constraint metrics were from ExAC release 0.3.1 ([@bib54]) file: *fordist_cleaned_nonpsych_z\_pli_rec_null_data.txt*. Two gene sets were created a constrained gene set where pLI \> 09 ([Tables S8](#mmc6){ref-type="supplementary-material"}B and S8D) and an unconstrained gene set with genes with pLI ≤ 0.9.

#### Curated List of Known Obesity or BMI Association Genes {#sec5.5.11.4}

The NHGRI-EBI GWAS catalog (<https://www.ebi.ac.uk/gwas/>, accessed on 25^th^ July 2017) was used to extract a list of obesity/BMI signals, reaching genome-wide significance (p value \< 5x10^−8^) in Europeans using the search terms "Body Mass Index," "Childhood body mass index," "Obesity," "Obesity (extreme)" and "Obesity (early onset extreme)." Using the reported gene for each signal, we identified 157 unique genes ([Tables S8](#mmc6){ref-type="supplementary-material"}B and S8E).

We performed gene set enrichment analysis similar to previous analyses ([@bib52], [@bib55]). Gene set analysis was performed on five primary groupings, each of which had subsets, resulting in 10 primary gene sets for analysis ([Table S9](#mmc7){ref-type="supplementary-material"}B). We repeated primary analysis in patients with obesity and developmental delay ([Table S9](#mmc7){ref-type="supplementary-material"}C) and with obesity alone ([Table S9](#mmc7){ref-type="supplementary-material"}D). A secondary analysis was performed to assess genes that were both LOF constrained (i.e., pLI \> 0.9) and GWAS ([Table S9](#mmc7){ref-type="supplementary-material"}E).

Briefly, using PLINK/SEQ (<https://atgu.mgh.harvard.edu/plinkseq/index.shtml>) we calculated gene region test-statistics for an enrichment of genetic variants in cases compared to controls. For each gene, we evaluated the three analysis groupings used in the gene-based tests: BROAD (MAF \< 1% and broadly damaging), STRICT (MAF \< 0.025% and strictly damaging), and LOF (MAF \< 0.025% and LoF). We then used the SMP utility to calculate the gene set enrichment while controlling for exome-wide differences between cases and controls. Twenty thousand case control permutations were used to estimate the empirical gene set enrichment p value. We report both the nominal p value and the adjusted p value, which adjusts for all ten primary gene sets investigated within each analysis grouping (i.e., BROAD, STRICT, and LOF). A Chi-square test of Independence was used to compare the overlap of genes in the GWAS gene set that were also LOF constrained.

### Functional Work Statistical Analysis {#sec5.5.12}

Distributions of average nuclei/cytoplasm ratio were compared between *PHIP* functionally studied variants seen only in cases and variants seen in controls by a Wilcoxon rank sum test.

### Mouse Statistical Analysis {#sec5.5.13}

For all analyses, the individual mouse was considered the experimental unit within the studies. All mutant data (7 females and 7 males) from the pipeline was collected across multiple batches and were compared to a year's worth of overlapping control data collected on mice from the same genetic background (up to 226 females and 231 males) for DEXA, ipGTT and CC (total 43 parameters). As a high-throughput project, the target sample size of 14 mutant animals per strain is relatively low. This was determined after a community-wide debate to find the lowest sample size that would balance resource usage while detecting phenotypic abnormalities. For analysis of continuous data, the current work uses linear mixed models to allow modeling of multiple sources of variability on a phenotype. The approach was previously discussed by Karp and colleagues ([@bib25]) as a way of integrating factors like genotype (G), sex (S) and genotype^∗^sex (G^∗^S) when performing phenotypic analysis of the mice. These factors are assumed to have a fixed values. Given our multi-batch experimental design strategy, linear mixed models also allow us to include batch effects as a random effect, with the assumption that animals from the same batch will have correlated phenotypes. This arises from factors such as technician skill, reagent lot, cage environment, maternal ability and genotype, and litter size. In the study of Karp and colleagues ([@bib25]) two equations were put forward: [Equation 1](#fd1){ref-type="disp-formula"} (below) includes G, S and G^∗^S and batch effect as described. Equation 2 is similar to [Equation 1](#fd1){ref-type="disp-formula"} but includes body weight as an additional factor affecting phenotype.

We used [Equation 1](#fd1){ref-type="disp-formula"} here since body weight is one of the phenotypes that we are interested in measuring and since body weight does not scale linearly (or at all) with many of the parameters that we are testing in our global phenotypic screen. Analysis were performed using PhenStat ([@bib30]), an R package version 2.18.0 available from Bioconductor ([@bib15]). The package's mixed model framework was used as default except the argument equationType was set to withoutWeight and dataPointsThreshold was set to 2. The genotype contribution test p value was adjusted for multiple testing to control the false discovery rate to 5%. This statistical method has been studied through simulations and resampling studies ([@bib26]) and found to be robust and reliable with a multi-batch workflow, where the knockout mice are split into multiple phenotyping batches. All statistics are shown in the corresponding figures ([Figures S6](#mmc1){ref-type="supplementary-material"} and [S7](#mmc1){ref-type="supplementary-material"}) and corresponding figure legends.

### Expression Data {#sec5.5.14}

Expression data and corresponding plots ([Figure S3](#mmc1){ref-type="supplementary-material"}) were obtained from <https://gtexportal.org/home/>.
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[^4]: Lead Contact

[^5]: Stage 1 included 927 SCOOP obesity cases and 4,057 INTERVAL controls; stage 2 included 1,810 SCOOP obesity cases and 2,647 Fenland controls. Test indicates whether it was a gene burden with very rare variants predicted to be LOF (LOF), or whether it included LOF as well as missense variants predicted deleterious by five *in silico* programs (STRICT). For infinite odds ratio (Inf), we provide an adjusted OR estimate by adding 0.5 to each of the contingency table cells (adj OR). Related to [Tables S2](#mmc3){ref-type="supplementary-material"} and [S6](#mmc5){ref-type="supplementary-material"}. Details of variants included in the tests are in [Table S6](#mmc5){ref-type="supplementary-material"}C.

[^6]: Stage 1 included 927 SCOOP cases and 4,057 INTERVAL controls; stage 2 included 1,810 obesity cases and 2,647 Fenland controls.

[^7]: M, male; F, female. BMI (kg/m^2^) shown for adults with age- and gender-adjusted standard deviation scores (SDS) shown in brackets for children under 18 years of age at referral. Height in cm (SDS). Birthweight (Bwt) SDS adjusted for gestational age. ✓ indicates reported presence of a phenotype. Fasting values for glucose and insulin reported: normal range for fasting plasma insulin = 0--60 pmol/L. @, on medication for type 2 diabetes. Speech and language delay represented as ✓σ.

[^8]: *De novo* inheritance established by genotyping both parents.

[^9]: Rare coding in family member.

[^10]: Presence of acanthosis nigricans (skin marker of insulin resistance).
